220 Participants Needed

Social Network Coaching for Cancer

(SONATA Trial)

LM
BG
Kah Poh Loh, B.Med.Sci., M.B.B.Ch., B.A ...
Overseen ByKah Poh Loh, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Rochester
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this study is to see if a social network support program (SOcial Networks to Activate Trust \& Adherence or SONATA) is helpful for older individuals receiving cancer treatment. The SONATA program will last for about 4 months. There are a total of 6 coaching sessions. The first 5 sessions will be held approximately every 1 to 2 weeks. Session 6 or the final session will be held approximately 1 to 2 months after session 5. Each session will last for about 1 to 2 hours.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems to focus on social support rather than medication changes.

What data supports the effectiveness of the treatment SONATA for cancer patients?

The study on improving adherence to endocrine hormonal therapy among breast cancer patients shows that support from a patient navigator and personalized communication can enhance treatment adherence, which is a key component of the SONATA approach. This suggests that similar strategies in SONATA could improve adherence and outcomes for cancer patients.12345

What makes the SONATA treatment unique for cancer patients?

The SONATA treatment is unique because it focuses on enhancing social networks to build trust and improve adherence to cancer therapy, rather than relying solely on medication. This approach emphasizes the importance of the patient-physician relationship and the patient's support system, which can significantly impact treatment compliance and overall quality of life.15678

Research Team

Kah Poh Loh, B.Med.Sci., M.B.B.Ch., B.A ...

Kah Poh Loh, MD

Principal Investigator

University of Rochester

Eligibility Criteria

This trial is for individuals aged 65 or older who have been diagnosed with cancer and are starting or within the first three months of oral cancer treatments. They must be able to consent, speak English, and identify at least one person from their social network to join them in the program.

Inclusion Criteria

I am 65 years old or older.
I have been diagnosed with cancer.
I am starting or have recently started oral cancer treatment.
See 2 more

Exclusion Criteria

Patient with any psychiatric or cognitive impairments interfering with participation as determined by the treating oncology team
Patient enrolled on oral anticancer therapeutic trials

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

SONATA Intervention

Participants engage in the SONATA social network support program, consisting of 6 coaching sessions over approximately 4 months

16 weeks
6 sessions (in-person or virtual)

Follow-up

Participants are monitored for adherence to oral anticancer treatments and other outcomes

4 weeks

Treatment Details

Interventions

  • SONATA
Trial Overview The SONATA program is being tested to see if it helps older adults with cancer by providing social support through coaching sessions. Participants will engage in six sessions over approximately four months aimed at enhancing trust and adherence to treatment.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Arm 1 - SONATA InterventionExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Rochester

Lead Sponsor

Trials
883
Recruited
555,000+

Findings from Research

In a study of 577 cancer patients, breast cancer patients showed significantly higher rates of non-adherence to adjuvant chemotherapy guidelines compared to colon cancer patients, with rates of 69% for primary non-adherence and 89% for non-persistence at 6 months.
Patient-centered communication (PCCM) was found to be a critical factor influencing adherence, with lower communication scores linked to higher non-adherence, particularly among older patients and those diagnosed with breast cancer.
Adjuvant chemotherapy non-adherence, patient-centered communication, and patient-level factors in elderly breast and colon cancer patients.Mitchell, KR., Boyle, JR., Juricekova, L., et al.[2023]
In a study of 7371 patients with operable IIIAN2 non-small-cell lung cancer, only 33.7% received all four recommended best treatment practices, highlighting a significant gap in adherence to guidelines.
Collective adherence to these best practices, including anatomic resection and induction therapy, was linked to improved survival rates, indicating that following these guidelines can lead to better patient outcomes.
Social determinants and facility type impact adherence to best practices in operable IIIAN2 lung cancer.Muslim, Z., Stroever, S., Baig, MZ., et al.[2023]
The study found significant variation in prostate cancer treatment rates, specifically prostatectomy, among different urologist subgroups based on their social networks, indicating that physician connections can influence treatment decisions.
In cities A, B, and C, certain urologist subgroups had notably lower odds of performing prostatectomies compared to others, even after accounting for patient characteristics, suggesting that physician networks play a crucial role in treatment variability.
Physician social networks and variation in prostate cancer treatment in three cities.Pollack, CE., Weissman, G., Bekelman, J., et al.[2022]

References

Adjuvant chemotherapy non-adherence, patient-centered communication, and patient-level factors in elderly breast and colon cancer patients. [2023]
Social determinants and facility type impact adherence to best practices in operable IIIAN2 lung cancer. [2023]
Physician social networks and variation in prostate cancer treatment in three cities. [2022]
Predictors of physician nonadherence to chemotherapy regimens. [2019]
Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial. [2020]
Patients' Trust in Physician, Patient Enablement, and Health-Related Quality of Life During Colon Cancer Treatment. [2018]
Compliance with cancer therapy by patients and physicians. [2019]
Network Modeling of Complex Time-Dependent Changes in Patient Adherence to Adjuvant Endocrine Treatment in ER+ Breast Cancer. [2022]